AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02522975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPIAO®
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study NCT02522975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPREX®
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study NCT05788354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUD insertion during cesarean section
Description: placement of IUD during cesarean section after placental delivery
Study NCT05788354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IUD insertion during cesarean section
Description: placement of IUD during cesarean section after placental delivery
Study NCT01081938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine
Study NCT01081938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine
Study NCT01081938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine
Study NCT00097370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepolizumab
Description: Study Drug
Study NCT02610257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical stimulus (vibration) applied on the forearm
Description: Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports.
Study NCT00799864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Patients will receive rilpivirine (RPV) tablet 25 milligram dose or an adjusted dose orally once daily in Cohort 1 (adolescents aged >=12 to \<18 years) up to 240 weeks. Patients will receive RPV weight-adjusted dose orally once daily in Cohort 2 (children aged >=6 to \<12 years) or 25 mg once daily for up to 48 weeks.
Study NCT00799864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Study NCT00799864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Study NCT00721331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline HCl + loratadine
Description: Topical
Study NCT00721331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline HCl
Description: Topical
Study NCT00721331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Description: Topical
Study NCT00721331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active ingredient free vehicle cream of CRx-197
Description: Topical
Study NCT02635282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Study NCT02635282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal fentanyl
Study NCT02635282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal midazolam
Study NCT00476931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-509
Description: 60 mg dose
Study NCT00476931 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT05084547 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00542347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole first
Description: * esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7
Study NCT00542347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic omeprazole first
Description: * generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7
Study NCT02959879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: curative surgery for resectable pancreatic duct adenocarcinoma
Description: curative surgery for resectable pancreatic duct adenocarcinoma
Study NCT02959879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard adjuvant chemotherapy
Description: 12 cycles of standard adjuvant chemotherapy are administrated
Study NCT02959879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: 8 cycles of standard adjuvant chemotherapy are administrated
Study NCT03423654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spatial Training
Description: Spatial Training using a 5x5 grid
Study NCT03423654 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Letter number matching
Description: Letter number matching
Study NCT02956096 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
Study NCT02956096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
Study NCT02956096 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: training on the running belt
Description: The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
Study NCT02956096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: training on the running belt
Description: The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
Study NCT01665508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Patient to start nebivolol and have repeat testing in 3 months
Study NCT01748773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 100 mg/m\^2 IV on Day 1 of Cycles 1-3.
Study NCT01748773 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
Study NCT01748773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine 850 mg/m\^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
Study NCT01748773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
Study NCT00235027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse Drug Event Monitoring
Description: The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
Study NCT02013882 — intervention group
Intervention type: PROCEDURE
Intervention: 1-1-12 wash-in
Description: wash-in phase during start of low flow anesthesia
Study NCT00955838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation technique
Description: 12 therapy session
Study NCT02811003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotation Medical Bioinductive Implant
Description: Placement of bioinductive implant over repair of insertional Achilles tendinopathy
Study NCT03071562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-mindfulness
Description: Sample class:~Warm-up~(15 minutes) Standing poses~(15 minutes) Balance poses~(15 minutes) Abdominals \& back bends (10 minutes) Cool-down~(5 minutes) Seated meditation Alternate nostril breathing Bellows breath Shoulder/neck stretches Cat-cow Forward fold Sun salutations Warrior 1 Warrior 2 Triangle Extended side angle Reverse warrior High lunge with twist Tree pose Standing holding knee Modified warrior 3 (chair support) Half moon~Bird-dog Side plank Bridge Cobra Sphinx Corpse pose Side-lying Seated om~Every month, a smudging ceremony will take place with an Aboriginal Elder for 5-10 minutes at the start of the class.
Study NCT01884701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENABLER-P Catheter System
Study NCT00473954 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EGEN-001 (phIL-12-005/PPC)
Description: In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals.
Study NCT04281472 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: efgartigimod PH20 SC in stage B
Description: Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
Study NCT04281472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC in stage B
Description: Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
Study NCT04281472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo in stage B
Description: Stage A: N/A, stage B: placebo
Study NCT02768701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.
Study NCT02768701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
Study NCT03168126 — intervention group
Intervention type: DEVICE
Intervention: Pro-AQT
Description: Use of the device for advanced hemodynamic monitoring
Study NCT03424915 — intervention group
Intervention type: BEHAVIORAL
Intervention: Harvard Health Professionals survey
Description: Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.
Study NCT03424915 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Participant will provide a blood sample
Study NCT03424915 — intervention group
Intervention type: OTHER
Intervention: CPET Procedures
Description: CPET with 12-lead ECG
Study NCT03424915 — intervention group
Intervention type: OTHER
Intervention: stool sample
Description: Research stool sample (within ±1 week of surgery), if possible
Study NCT03424915 — intervention group
Intervention type: PROCEDURE
Intervention: Research Tissue sampling
Description: Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.
Study NCT00799864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).
Study NCT00799864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Study NCT00799864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Study NCT03728231 — intervention group
Intervention type: OTHER
Intervention: Complete blood count
Description: taking blood sample from venous blood
Study NCT03133780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
Study NCT03133780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
Study NCT03024671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch test application
Description: test patch with cosmetic product will be applied to the back
Study NCT02048813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02048813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02048813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02048813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02048813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02048813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT02048813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT02048813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02048813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02048813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02048813 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT01660685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracking
Description: Participants will record their daily weight, physical activity steps and meal replacements online
Study NCT01660685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journaling
Description: Participants will journal to two online writing prompts: one on positive focus and one on goal setting
Study NCT01660685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website
Description: Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
Study NCT01660685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
Study NCT01660685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
Study NCT01433588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Calmer
Description: This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
Study NCT01433588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
Study NCT04010253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMEOX
Description: Instrumental airway clearance by the medical device SIMEOX
Study NCT04010253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Description: Manual aiway clearance by autogenic drainage
Study NCT05025917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shatavari
Description: Shatavari root powder
Study NCT04112264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency ablation
Description: a radiofrequency cannula is advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia along the area of knee joint supplied by that respected genicular nerve by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
Study NCT05025917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium stearate
Description: Magnesium stearate powder
Study NCT01986322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP/HB/Hib vaccine
Description: Dosage equal to 0.5 mL administered intramuscularly
Study NCT01986322 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP/HB and Hib vaccine
Description: Dosage equal to 0.5 mL administered intramuscularly
Study NCT00629642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Oral, 10mg
Study NCT00629642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Oral, 5mg
Study NCT04112264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar radiofrequency ablation
Description: Two radiofrequency cannula are advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
Study NCT02036086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Drug
Study NCT02036086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Drug
Study NCT01328652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexlansoprazole
Description: dexlansoprazole 60 mg once daily for 3 months
Study NCT01698645 — intervention group
Intervention type: DRUG
Intervention: PecFent® (fentanyl) nasal spray